- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07901413
Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
Studieoversigt
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Jingnan Yang
- Telefonnummer: 010-66609990
- E-mail: CO-Clinicaltrial@innocarepharma.com
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekruttering
- Fudan University Shanghai Cancer Center
-
Kontakt:
- DingWei Ye, M.D.
- Telefonnummer: 021-64175590*81807
- E-mail: dwyeli@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants must be at least 18 years old.
- Participants thoroughly understand study procedures, and voluntarily sign the written ICF
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
- Expected survival time ≥3 months.
- Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
- Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
- The organ function level must meet the prescribed standards
- All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
- Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
- Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
- Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
- Participants can communicate well with the Investigator and can complete the study according to the study protocol
Exclusion Criteria:
- Other active malignant tumors occurred within 3 years before the first administration of the study drug
- Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
- Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
- Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
- Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
- Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
- Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
- Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
- Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
- Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
- Situations that the investigator deems unsuitable for participating in this study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ICP-B381
|
ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first). |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Tidsramme: 2 years
|
2 years
|
|
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Tidsramme: 2 years
|
2 years
|
|
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Tidsramme: 2 years
|
2 years
|
|
The optimal dosing regimen for the subsequent study of ICP-B381
Tidsramme: 2 years
|
2 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Samlet overlevelse (OS)
Tidsramme: 2 år
|
2 år
|
|
Varighed af svar (DOR)
Tidsramme: 2 år
|
2 år
|
|
Objektiv svarprocent (ORR)
Tidsramme: 2 år
|
2 år
|
|
Maksimal koncentration (Cmax)
Tidsramme: 2 år
|
2 år
|
|
Disease Control Rate (DCR)
Tidsramme: 2 år
|
2 år
|
|
Time to Maximum Plasma Concentration (Tmax)
Tidsramme: 2 years
|
2 years
|
|
Half-life (T1/2)
Tidsramme: 2 years
|
2 years
|
|
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Tidsramme: 2 years
|
2 years
|
|
Apparent Clearance Rate (CL/F)
Tidsramme: 2 years
|
2 years
|
|
Terminal Apparent Volume of Distribution (Vz/F)
Tidsramme: 2 years
|
2 years
|
|
Steady-state Pharmacokinetic Parameters
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: PSA90 response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer:12-week PSA response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: time to PSA progression (TTPP)
Tidsramme: 2 years
|
2 years
|
|
Time to First Subsequent Therapy (TFST)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Tidsramme: 2 years
|
2 years
|
|
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Tidsramme: 2 years
|
2 years
|
|
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
Tidsramme: 2 years
|
2 years
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ICP-CL-01901
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .